Analysts think QNCX stock price could increase by 437%
Dec 25, 2024, 12:26 PM
-6.73%
What does QNCX do
Quince Therapeutics, based in South San Francisco, develops therapeutics using its AIDE technology to encapsulate drugs in patients' red blood cells, targeting rare diseases like Ataxia-Telangiectasia. The company went public on May 9, 2019, and employs 32 people.
5 analysts think QNCX stock price will increase by 436.84%. The current median analyst target is $9.18 compared to a current stock price of $1.71. The lowest analysts target is $6.06 and the highest analyst target is $12.60.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
